LyondellBasell Industries N.V. Class A
LYB
$0.00
-4.78%
LyondellBasell Industries is a global petrochemical producer operating in the Specialty Chemicals industry. It is the world's largest producer of polypropylene, with a core advantage stemming from its extensive North American production base and diversified chemical portfolio.
LYB
LyondellBasell Industries N.V. Class A
$0.00
Related headlines
Investment Opinion: Should I buy LYB Today?
Based on a synthesis of the data, the objective assessment is a Hold. The powerful technical breakout and analyst upgrades suggest a potential inflection point, making it too risky to short or sell aggressively. However, the severe fundamental weakness, high leverage, and cyclical uncertainty mean the stock is not a compelling buy at current levels near its 52-week high. Investors should await more concrete evidence of sustained margin improvement and earnings recovery before establishing new long positions. The forward P/E of 17.77, based on optimistic EPS estimates, is not cheap for a cyclical stock at this stage of recovery.
Sign up to view all
LYB 12-Month Price Forecast
The AI assessment is neutral with medium confidence. The explosive price move appears to have front-run the fundamental recovery story. While the setup for a cyclical rebound exists, the risk/reward at the current price is balanced, favoring a wait-and-see approach for clearer confirmation of improving financials.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on LyondellBasell Industries N.V. Class A's 12-month outlook, with a consensus price target around $0.00 and implied upside of — versus the current price.
Average Target
$0.00
10 analysts
Implied Upside
—
vs. current price
Analyst Count
10
covering this stock
Price Range
$0 - $0
Analyst target range
Wall Street analyst coverage for LyondellBasell shows a consensus that expects a significant earnings recovery, with an average EPS estimate of $5.52 for the upcoming period, ranging from $3.91 to $7.35. Recent institutional ratings reflect a mix of views, with actions in March 2026 including upgrades from Citigroup (to Buy from Neutral), RBC Capital (to Outperform from Sector Perform), and Fermium Research (to Buy from Hold), alongside several reiterations of Hold or Neutral ratings. This suggests a cautiously optimistic shift among some analysts regarding the company's prospects.
Bulls vs Bears: LYB Investment Factors
LYB presents a stark dichotomy: exceptionally strong technical momentum and analyst optimism for a recovery are juxtaposed against deeply challenged fundamentals and high cyclical risk. The investment thesis hinges entirely on the timing and magnitude of an earnings rebound in a volatile industry.
Bullish
- Strong Technical Momentum: Stock up 86% in 3 months, near 52-week high, showing powerful uptrend.
- Analyst Upgrades & Recovery Outlook: Recent upgrades to Buy/Outperform; consensus EPS forecast of $5.52 signals expected profit rebound.
- Attractive Sales-Based Valuation: Low PS ratio of 0.46 and EV/Sales of 1.24 suggest potential undervaluation relative to revenue.
- Robust Free Cash Flow: Generated $2.26B in TTM FCF, providing financial flexibility despite earnings volatility.
Bearish
- Severe Fundamental Weakness: Q4 revenue down 25.3% YoY; net loss of $140M with negative margins.
- High Financial Leverage: Debt-to-equity of 1.58 indicates a leveraged balance sheet, increasing risk in a downturn.
- Poor Profitability Metrics: Negative ROE (-7.37%) and low ROA (1.69%) reflect operational challenges.
- Cyclical Industry Downturn: Facing one of the longest chemical industry slumps, pressuring prices and volumes.
LYB Technical Analysis
The stock has demonstrated a powerful uptrend over the past six months, rising 63.3% from its lows in late October 2025. This momentum accelerated sharply in the last three months, with the price surging 86.1%, significantly outperforming the broader market which declined 4.63% over the same period. The short-term performance is exceptionally strong, with a 40.1% gain over the past month, driven by a rapid climb from around $57 in early February to over $80 by the end of March. The stock's relative strength over one month is a remarkable 45.3 percentage points above the market. The current price of $80.56 is near the upper end of its 52-week range of $41.58 to $83.94, representing a recovery of over 90% from the low. The price is just 4.0% below the 52-week high, indicating the stock is in a position of significant strength.
Beta
0.67
0.67x market volatility
Max Drawdown
-45.5%
Largest decline past year
52-Week Range
$42-$84
Price range past year
Annual Return
+9.5%
Cumulative gain past year
| Period | LYB Return | S&P 500 |
|---|---|---|
| 1m | +32.5% | -3.7% |
| 3m | +77.2% | -4.1% |
| 6m | +55.1% | -2.1% |
| 1y | +9.5% | +16.1% |
| ytd | +72.8% | -3.9% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
LYB Fundamental Analysis
Revenue and profitability have been under significant pressure, with Q4 2025 revenue of $7.09 billion declining 25.3% year-over-year. The company reported a net loss of $140 million for the quarter, with a negative net margin of -1.97%, continuing a trend of volatile earnings seen throughout 2025. Financial health shows a debt-to-equity ratio of 1.58, indicating a leveraged balance sheet, but this is supported by a solid current ratio of 1.77. The company generated strong free cash flow of $2.26 billion over the trailing twelve months, providing liquidity despite the earnings challenges. Operational efficiency metrics are weak, with a negative Return on Equity (ROE) of -7.37% and a low Return on Assets (ROA) of 1.69%, reflecting the difficult operating environment and margin compression in the chemical cycle.
Quarterly Revenue
$7.1B
2025-12
Revenue YoY Growth
-0.25%
YoY Comparison
Gross Margin
+0.06%
Latest Quarter
Free Cash Flow
$2.3B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is LYB Overvalued?
Given the company's negative net income, the trailing P/E ratio is not meaningful. Therefore, the Price-to-Sales (PS) ratio of 0.46 and Enterprise Value-to-Sales (EV/Sales) ratio of 1.24 are more appropriate valuation metrics. These ratios suggest the market is valuing the company at a significant discount to its sales, likely reflecting the cyclical downturn and compressed margins. The forward P/E ratio based on analyst estimates is 17.77, which provides a forward-looking valuation anchor assuming a return to profitability. Data for a direct peer comparison with industry averages is not available in the provided inputs.
PE
-18.8x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range -25x~42x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
22.3x
Enterprise Value Multiple
Investment Risk Disclosure
LYB's risk profile is elevated, dominated by cyclical and operational factors. Financially, the company carries significant leverage with a debt-to-equity ratio of 1.58, which could strain the balance sheet if the industry downturn persists longer than expected. Operationally, profitability is severely impaired, with negative net and operating margins in Q4 2025, driven by a 25.3% year-over-year revenue decline. This reflects the deep trough of the chemical cycle, characterized by oversupply and weak demand. Externally, recent news highlights acute geopolitical risks, including Middle East naphtha supply disruptions that threaten production costs and output. Furthermore, the company's drastic dividend cut signals management's view of prolonged headwinds and limited near-term cash generation, adding credibility risk. While strong free cash flow provides a liquidity buffer, the stock's recent parabolic rise of over 86% in three months introduces substantial technical risk of a sharp pullback if the fundamental recovery narrative falters.
FAQ
The key risks are cyclical, financial, and operational. The chemical industry is in a prolonged downturn, which could further pressure revenues and margins. Financially, the company has high leverage with a debt-to-equity ratio of 1.58. Operationally, profitability is poor, with negative ROE and recent quarterly losses. Additionally, geopolitical events can disrupt supply chains and input costs, as seen with recent Middle East naphtha issues. The stock's parabolic rise also introduces high volatility risk.
The 12-month outlook is highly dependent on the earnings recovery. The base case (50% probability) sees a gradual recovery with a target range of $75-$90, based on achieving the consensus EPS of $5.52 and a stable forward P/E. The bull case (30%) could drive the stock to $95-$110 on a faster rebound, while the bear case (20%) risks a pullback to $50-$65 if the cycle trough deepens. Analyst price targets are not explicitly provided, but their EPS estimates range from $3.91 to $7.35, indicating significant forecast uncertainty.
LYB's valuation sends mixed signals. Based on sales, it appears cheap with a Price-to-Sales ratio of 0.46. However, this reflects currently depressed margins. Based on forward earnings, the P/E of 17.77 is reasonable but not deeply undervalued for a cyclical stock. The valuation is fair if the company hits its $5.52 EPS target, but risky if the recovery is delayed. It is not clearly overvalued or undervalued, but rather appropriately valued for the recovery scenario.
At the current price near its 52-week high, LYB is not a compelling buy for new investors. While analyst upgrades and a powerful uptrend are positive, the stock has already surged 86% in three months, largely pricing in a recovery. The fundamental picture remains weak with a Q4 net loss and negative margins. A more prudent strategy would be to wait for a better entry point or for quarterly results to confirm the expected earnings rebound.
LYB is primarily suitable for medium-to-long-term investors who can tolerate high volatility and are betting on a full chemical cycle recovery. The short-term outlook is extremely volatile due to the stock's parabolic move and quarterly earnings uncertainty. Long-term investors may benefit from the company's leading market position and low valuation multiples if the cycle turns, but they must be prepared for potential further downside and a holding period of several years to realize the investment thesis.